Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2019 08:00 ET | Source: Zogenix, Inc.

Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome

EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling...
February 01, 2019 16:43 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
January 02, 2019 16:05 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
December 03, 2018 16:05 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
December 03, 2018 09:00 ET | Source: Zogenix, Inc.

Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome

Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo ...
December 02, 2018 09:00 ET | Source: Zogenix, Inc.

Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome

Data Presented During Late-Breaker Session at 72nd American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, Calif., Dec. 02, 2018 ...
November 29, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting

EMERYVILLE, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that it will...
November 27, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in the Global Mizuho Investor Conference 2018

EMERYVILLE, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
November 26, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Announce New Data at 72nd American Epilepsy Society Annual Meeting

Full Results from Second Pivotal Phase 3 Trial of FINTEPLA® (ZX008) in Dravet Syndrome (Study 1504) New Long-Term Efficacy and Safety Data from Open-Label Extension Trial (Study 1503) Studies on the...
November 08, 2018 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Third Quarter Financial Results

Reported positive top-line results from second pivotal Phase 3 trial of FINTEPLA® (ZX008) in patients with Dravet syndrome, Study 1504Initiated rolling NDA submission to FDA for FINTEPLAContinued to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right